Is there a Bearish outlook for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) this week?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo
Investors sentiment increased to 1.43 in 2019 Q1. Its up 0.35, from 1.08 in 2018Q4. It is positive, as 23 investors sold Sarepta Therapeutics, Inc. shares while 88 reduced holdings. 57 funds opened positions while 102 raised stakes. 74.26 million shares or 13.02% more from 65.70 million shares in 2018Q4 were reported.
Moore Capital Management Lp stated it has 0.03% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Mirae Asset Global has invested 0% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Utd Capital Fincl Advisers Llc reported 0.01% stake. Lpl Ltd Liability Com owns 13,179 shares or 0% of their US portfolio. Citigroup Inc invested 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Orbimed Limited Co holds 1.53% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 828,400 shares. The California-based Parallax Volatility Advisers Limited Partnership has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). New England Private Wealth Advsr Lc stated it has 1,988 shares. Goldman Sachs Grp holds 673,273 shares or 0.02% of its portfolio. Oppenheimer Asset Management owns 356 shares. Pennsylvania-based Susquehanna Group Llp has invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Timessquare Mgmt Limited Liability Com reported 1.10 million shares stake. Barclays Public Ltd Com has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Blackrock has 4.19 million shares for 0.02% of their portfolio. Gam Holding Ag stated it has 0.2% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Since August 12, 2019, it had 2 buys, and 0 selling transactions for $2.16 million activity. $159,250 worth of stock was bought by Barry Richard on Monday, August 12.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 15 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sarepta Therapeutics has $270 highest and $16500 lowest target. $203.56’s average target is 66.89% above currents $121.97 stock price. Sarepta Therapeutics had 33 analyst reports since February 19, 2019 according to SRatingsIntel. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Monday, March 25 by Needham. Morgan Stanley maintained it with “Overweight” rating and $169 target in Monday, March 4 report. The firm has “Buy” rating given on Monday, February 25 by JMP Securities. The firm earned “Buy” rating on Tuesday, June 25 by Cantor Fitzgerald. The firm has “Buy” rating by RBC Capital Markets given on Thursday, February 28. On Thursday, February 28 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The company was maintained on Wednesday, February 27 by H.C. Wainwright. Piper Jaffray maintained the shares of SRPT in report on Friday, June 21 with “Buy” rating. The firm has “Buy” rating given on Monday, March 25 by H.C. Wainwright. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Wednesday, February 27 by SunTrust. Below is a list of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) latest ratings and price target changes.

09/07/2019 Broker: Inc. – Common Stock Rating: Morgan Stanley New Target: $165.0000 220.0000
01/07/2019 Broker: Inc. – Common Stock Rating: Rbc Capital New Target: $188.0000 220.0000
25/06/2019 Broker: Cantor Fitzgerald Rating: Buy New Target: $231 Maintain
21/06/2019 Broker: Piper Jaffray Rating: Buy New Target: $208 Maintain
16/05/2019 Broker: Inc. – Common Stock Rating: Citigroup New Target: $201.0000 190.0000
09/05/2019 Broker: Inc. – Common Stock Rating: Rbc Capital New Target: $191.0000 188.0000
26/04/2019 Broker: BidaskScore Rating: Hold Upgrade
12/04/2019 Broker: Evercore Rating: Outperform New Target: $175 Initiates Coverage On
26/03/2019 Broker: Citigroup Rating: Buy New Target: $201 Maintain
25/03/2019 Broker: J.P. Morgan Rating: Buy Maintain

The stock decreased 1.31% or $1.62 during the last trading session, reaching $121.97. About 962,745 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 29.09% since August 15, 2018 and is uptrending. It has outperformed by 29.09% the S&P500.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $9.07 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Seekingalpha.com which released: “Sarepta: When You Sell Too Early And Want Back In – Seeking Alpha” on June 25, 2019, also Seekingalpha.com with their article: “Sarepta: Buy The Pfizer Selloff – Seeking Alpha” published on May 01, 2019, Seekingalpha.com published: “Sarepta Therapeutics Q4 Earnings Preview – Seeking Alpha” on February 26, 2019. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Nasdaq.com and their article: “Health Care Sector Update for 03/25/2019: SRPT,NK,MDWD – Nasdaq” published on March 25, 2019 as well as Fool.com‘s news article titled: “The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On – The Motley Fool” with publication date: July 17, 2019.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.